Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1969 1
1970 1
1971 1
1972 3
1973 1
1976 1
1977 1
1978 1
1979 4
1983 5
1984 3
1985 1
1986 1
1987 5
1988 3
1989 3
1990 7
1991 6
1992 8
1993 6
1994 5
1995 2
1996 5
1997 15
1998 4
1999 10
2000 10
2001 10
2002 11
2003 13
2004 12
2005 16
2006 26
2007 16
2008 13
2009 22
2010 17
2011 17
2012 11
2013 18
2014 21
2015 19
2016 26
2017 30
2018 26
2019 21
2020 31
2021 27
2022 16
2023 17
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
NEW CLASSIFICATION SYSTEM: The International Consensus Classification distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former might mimic essential thrombocythemia (ET) in its presentation. Approximately 15% of patients with ET or polycythemia vera (PV) might p …
NEW CLASSIFICATION SYSTEM: The International Consensus Classification distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former mi …
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23. Am J Hematol. 2020. PMID: 32974939 Free article. Review.
DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding …
DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively chara …
JAK: Not Just Another Kinase.
Agashe RP, Lippman SM, Kurzrock R. Agashe RP, et al. Mol Cancer Ther. 2022 Dec 2;21(12):1757-1764. doi: 10.1158/1535-7163.MCT-22-0323. Mol Cancer Ther. 2022. PMID: 36252553 Free PMC article. Review.
JAKs (JAK1, JAK2, JAK3, and TYK2) noncovalently associate with cytokine receptors, mediate receptor tyrosine phosphorylation, and recruit 1 STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6). ...Both germline mutations and polymorphisms of JAK family mem …
JAKs (JAK1, JAK2, JAK3, and TYK2) noncovalently associate with cytokine receptors, mediate receptor tyrosine phosphorylation, and recruit …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutations are also prevalent in the closely related MPNs, namely polycythemia vera (PV) and essential thrombocythemia (ET). The 2016 World …
Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutati …
Genetic basis and molecular profiling in myeloproliferative neoplasms.
Luque Paz D, Kralovics R, Skoda RC. Luque Paz D, et al. Blood. 2023 Apr 20;141(16):1909-1921. doi: 10.1182/blood.2022017578. Blood. 2023. PMID: 36347013 Free PMC article. Review.
The 3 subtypes, that is, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are diagnosed according to the World Health Organization (WHO) and international consensus classification (ICC) criteria. Acquired gain-of-function mutations i …
The 3 subtypes, that is, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are diagnosed accor …
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, Barbui T, Arber DA, Tefferi A. Thiele J, et al. Am J Hematol. 2023 Jan;98(1):166-179. doi: 10.1002/ajh.26751. Epub 2022 Oct 14. Am J Hematol. 2023. PMID: 36200127 Free article. Review.
This current in-depth review focuses on the ICC-2022 category of JAK2 mutation-prevalent myeloproliferative neoplasms (MPNs): essential thrombocythemia, polycythemia vera, primary myelofibrosis, and MPN, unclassifiable. ...
This current in-depth review focuses on the ICC-2022 category of JAK2 mutation-prevalent myeloproliferative neoplasms (MPNs): essential t …
A Review and Assessment of Drug-Induced Thrombocytosis.
Vo QT, Thompson DF. Vo QT, et al. Ann Pharmacother. 2019 May;53(5):523-536. doi: 10.1177/1060028018819450. Epub 2018 Dec 10. Ann Pharmacother. 2019. PMID: 30525921 Review.
MEDLINE/PubMed (1966 to September 2018) was searched using the MeSH terms thrombocytosis/chemically-induced and thrombocytosis/etiology. EMBASE (1980 to September 2018) was searched using the EMTAGS thrombocytosis/side effect. ...DATA SYNTHESIS: Drug-induced …
MEDLINE/PubMed (1966 to September 2018) was searched using the MeSH terms thrombocytosis/chemically-induced and thrombocytosis …
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38269572 Review.
Leukemic transformation rate at 10 years is <1% but might be higher in JAK2-mutated patients with extreme thrombocytosis and those with abnormal karyotype. ...ADDITIONAL CONTENT: The current review includes specific treatment strategies in the context of extreme …
Leukemic transformation rate at 10 years is <1% but might be higher in JAK2-mutated patients with extreme thrombocytosis an …
Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J, Chatain N, Sofias AM, Lammers T, Koschmieder S. Baumeister J, et al. Cells. 2021 Dec 16;10(12):3551. doi: 10.3390/cells10123551. Cells. 2021. PMID: 34944059 Free PMC article. Review.
Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) are a heterogeneous group of hematologic malignancies, including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), as well as post-PV-MF and post-ET-MF. ...
Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) are a heterogeneous group of hematologic malignancies, including essential …
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM, Lasho T. Patnaik MM, et al. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):460-464. doi: 10.1182/hematology.2020000163. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275673 Free PMC article. Review.
They consist of four adult onset entities including chronic myelomonocytic leukemia (CMML), MDS/MPN-ring sideroblasts-thrombocytosis (MDS/MPN-RS-T), BCR-ABL1 negative atypical chronic myeloid leukemia (aCML) and MDS/MPN-unclassifiable (MDS/MPN-U); with juvenile myelomonocy …
They consist of four adult onset entities including chronic myelomonocytic leukemia (CMML), MDS/MPN-ring sideroblasts-thrombocytosis …
497 results